Phaseline

Companies › TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)

TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics): clinical trials, targets and expected readouts

3 active drug programs in 5 registered trials: 5 Phase 1; Oncology; next expected readout Aug 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
BBO-10203
PI3Kα:RAS breaker
PIK3CA, KRAS, NRAS, HRASPhase 1Non-Small Cell Lung Cancer; Solid Tumor, Adult; Non-small Cell Lung CancerAug 2027
BBO-11818
pan-KRAS inhibitor
KRASPhase 1Non-Small Cell Lung CancerAug 2027
BBO-8520
KRAS G12C ON and OFF inhibitor
KRASPhase 1Non-small Cell Lung CancerApr 2031

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06917079BBO-11818Phase 1Non-Small Cell Lung CancerOncologyAug 2027
NCT06917079BBO-10203Phase 1Non-Small Cell Lung CancerOncologyAug 2027
NCT06625775BBO-10203Phase 1Solid Tumor, AdultOncologyNov 2028
NCT06343402BBO-10203Phase 1Non-small Cell Lung CancerOncologyApr 2031
NCT06343402BBO-8520Phase 1Non-small Cell Lung CancerOncologyApr 2031

Targets

KRAS (3) PIK3CA (1) NRAS (1) HRAS (1)

Companies with the same targets

Eli Lilly Revolution Medicines Adlai Nortye Biopharma Roche Novartis Quanta Therapeutics Guangzhou JOYO Pharma Shanghai YingLi Pharmaceutical Bristol-Myers Squibb Amgen

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.